BioSpace News Archive

Drug Development

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

Astellas Pharma Inc. and Seattle Genetics, Inc. announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

June 3, 2018
·
10 min read
Drug Development

Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings from a Phase 2 study that showed treatment with erdafitinib.

June 3, 2018
·
7 min read
Biotech Beach

Bruker Introduces scimaX™ MRMS for Novel Phenomics Workflows, and Further Enhances the timsTOF™ Pro for PASEF Proteomics at ASMS

At the 66th ASMS Conference, Bruker announces innovative mass spectrometry products and workflows for breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in novel biopharma applications and in applied toxicology and forensics markets.

June 3, 2018
·
11 min read
Drug Development

Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018

June 3, 2018 13:00 UTC Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018 – Cabozantinib improved overall survival and progression-free survival irrespective of duration of prior sorafenib treatment or age category – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXE

June 3, 2018
·
15 min read
Drug Development

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

Genosco announced data from a Phase 1/2 study evaluating lazertinib (YH25448, GNS-1480) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 3, 2018
·
5 min read
FDA

NANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine

NANT announced on June 3 that the Food and Drug Administration authorized clinical trials for the company’s investigational neoepitope yeast vaccine, YE-NEO-011, for a personalized, next-generation cancer immunotherapy.

June 3, 2018
·
5 min read
Drug Development

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA® (venetoclax) in previously-untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.

June 3, 2018
·
15 min read
Drug Development

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive daytime sleepiness (EDS) in the global Phase 2/3 EXPRESS study of pediatric patients seven to 17 years of age with narcolepsy.

June 3, 2018
·
8 min read